Delivery of therapeutics to the inner ear: The challenge of the blood-labyrinth barrier

302Citations
Citations of this article
220Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Permanent hearing loss affects more than 5% of the world’s population, yet there are no nondevice therapies that can protect or restore hearing. Delivery of therapeutics to the cochlea and vestibular system of the inner ear is complicated by their inaccessible location. Drug delivery to the inner ear via the vasculature is an attractive noninvasive strategy, yet the blood-labyrinth barrier at the luminal surface of inner ear capillaries restricts entry of most blood-borne compounds into inner ear tissues. Here, we compare the blood-labyrinth barrier to the blood-brain barrier, discuss invasive intratympanic and intracochlear drug delivery methods, and evaluate noninvasive strategies for drug delivery to the inner ear.

Cite

CITATION STYLE

APA

Nyberg, S., Joan Abbott, N., Shi, X., Steyger, P. S., & Dabdoub, A. (2019). Delivery of therapeutics to the inner ear: The challenge of the blood-labyrinth barrier. Science Translational Medicine, 11(482). https://doi.org/10.1126/scitranslmed.aao0935

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free